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1116-32 Getting Risk Factors to Goal: Lifestyle Intervention Is 
Worth the Effort in Patients With Hypertension, 
Hyperlipidemia, and/or Hyperglycemia
Neil F. Gordon, Richard D. Salmon, William E. Saxon, Kevin S. Reid, George C. Faircloth, 
Ivan Levinrad, Brenda S. Mitchell, Richard F. Leighton, Laurence S. Sperling, William L. 
Haskell, Barry A. Franklin, St. Joseph's/Candler Health System, Savannah, GA, 
INTERVENT Coordinating Center, Savannah, GA
Background: Hypertension, hyperlipidemia, and hyperglycemia are leading causes of
potentially avoidable morbidity, mortality, and healthcare expenditures. National clinical
guidelines promulgate therapeutic lifestyle changes (TLC) as a standard of care in the
management of these cardiovascular disease risk factors. Because of the widespread
availability of pharmacotherapeutic agents, however, the value of TLC per se in contem-
porary medical practice is often discounted by clinicians and health insurers. The aim of
this study was to evaluate the precise role of TLC in helping patients achieve goal risk
factor levels.
Methods: We studied the effect of TLC on the control of: blood pressure (BP) in unmedi-
cated patients with a baseline systolic BP > 140 mmHg (n=335) and/or diastolic BP > 90
mmHg (n=346); LDL cholesterol in unmedicated patients with a baseline value > 100 mg/
dl (n = 1,553); and fasting blood glucose in unmedicated patients with a baseline value >
110 mg/dl (n=249). TLC included exercise training and nutrition counseling. Interventions
were based on several well established behavior change models. Patients remained
unmedicated throughout the study and were evaluated at baseline and after 3 months of
TLC.
Results: Systolic BP decreased from 149 + 10 to 133 + 15 mmHg (p<0.05) and 63% of
patients achieved goal (i.e., <130 mmHg for patients with diabetes and/or atherosclero-
sis; <140 mmHg for others). Diastolic BP decreased from 95 + 5 to 85 + 9 mmHg
(p<0.05) and 65% of patients achieved goal (i.e., <80 mmHg for patients with diabetes;
<85 mmHg for patients with atherosclerosis; <90 mmHg for others). LDL cholesterol
decreased from 143 + 28 to 134 + 30 mg/dl (p<0.05) and 27% of patients achieved goal
(using ATP III criteria). Fasting glucose decreased from 144 + 43 to 129 + 43 mg/dl and
41% of patients achieved goal (i.e. <110 mg/dl); of patients with a baseline value compat-
ible with diabetes (i.e., >125 mg/dl; n=141), 35% achieved a value <125 mg/dl.
Conclusion: These data show that many patients with classic cardiovascular disease
risk factors can achieve goal without medications within 3 months of initiating TLC and
refute the notion that intensive lifestyle intervention is not worth the effort.
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1116-33A Effect of Lipid Subfractions on Progression of Coronary 
Artery Disease Among Middle-Aged Women
Adhir Shroff, Kristina Orth-Gomer, Julia Fridman, Imre Janszky, Bertil Svane, Richard L. 
Kirkeeide, Karin Schenck-Gustafsson, Murray A. Mittleman, Beth Israel Deaconess 
Medical Center, Boston, MA, Karolinska Institutet, Stockholm, Sweden
Background: As part of the Stockholm Female Coronary Risk Study we studied the
effects of lipid parameters on progression of CAD among a cohort of 84 women who
were 65 years or younger with established CAD, not taking lipid lowering medications,
and underwent serial quantitative coronary angiography (QCA) at baseline (between
1991-1994) and after 3 years.
Methods: An average of 3 months after an acute coronary syndrome the women sup-
plied clinical and demographic data and a fasting blood sample. The association between
each lipid parameter and change in mean luminal diameter in up to 10 coronary seg-
ments was estimated using multivariable mixed model analysis of variance controlling for
age, index event, diabetes, hypertension, smoking, BMI, menopausal status, and hor-
mone use.
Results: There were 568 evaluable coronary segments among the 84 women. The table
shows that each of the standard lipid parameters (total cholesterol, LDL, HDL, triglycer-
ides) and apolipoprotiens (ApoB, ApoA1, VLDL) significantly predicted progression while
Lp(a) did not. The strongest and most consistent associations were found for non-HDL
cholesterol and the ratio chol:HDL. Furthermore, after including either non-HDL choles-
terol or chol:HDL in the model, none of the other lipid parameters significantly improved
the prediction of CAD progression.
Conclusion: Non-HDL cholesterol and the ratio of chol:HDL were the best predictors of
progression of CAD among this cohort of middle-aged women with established disease.
Noon
1116-33 Renal Transplant Function as a Risk Factor for 
Cardiovascular Events and for All Cause Mortality in a 
Renal Transplant Population: Experience From the 
ALERT Trial
Bengt Fellström, H. Holdaas, A. Jardine, E. Cole, G. Nyberg, C. Gronhagen-Riska, S. 
Madsen, H. Neumayer, B. Maes, P. Ambuhl, I. Holme, P. Faucald, T. Pedersen, The 
ALERT Study Investigators, University Hospital, Uppsala, Sweden
Background: ALERT was a randomized, placebo-controlled, study of the effects of Fluv-
astatin on cardiovascular and renal endpoints in transplant recipients with a stable renal
function followed for 5-6 years. The design and major outcomes have been published
(Lancet, June 14, 2003). In this population the role of conventional cardiac risk factor has
not been fully established. Methods: A univariate risk factor analysis was performed in
the placebo group to assess the influence of creatinine as a risk factor for cardiovascular
and non cardiovascular endpoints. Results: A total of 2102 patients ( total cholesterol
155-348 mg/dl) were recruited, of whom 1052 received placebo. The mean age was 50
years ( 30-75) , 66% male, 85% first transplant recipients and 22 % live donor recipients.
The average serum creatinine at inclusion was 147 umol/l (range 70- 300).The relative
risk for a 10 unit increase in creatinine and the frequency of events in the 1st quartile
(<111 umol/L) compared with the 4th Q ( >167 umol/L) are presented : 
*MACE (Major Adverse Cardiac Event: cardiac death, MI, revascularization procedure)
Conclusion: In renal transplant recipients with stable function, serum creatinine is a risk 
factor for MACE, cardiac death, cardiac death, non-cardiovascular mortality and all cause 
mortality but not for stroke or non-fatal myocardial infarction. These findings are borne 
out in multivariate analyses adjusting for other cardiovascular risk factors.
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1116-34 Inhibition of 3-Hydroxy-3-Methylglutaryl Coenzyme a 
Reductase Attenuates Expression of Inducible Nitric 
Oxide Synthase in Cardiac Myocytes: A Possible Link 
With Direct Myocardial Protection During Ischemia-
Reperfusion
Rosalinda Madonna, Pericle Di Napoli, Marika Massaro, Alfredo Grilli, Mario Felaco, 
Yong-Jian Geng, Rafffaele De Caterina, University of Chieti, Cardiology Division, Chieti, 
Italy
Cytokine-induced nitric oxide (NO) is implicated in myocardial apoptosis. Since statins
reduce myocardial apoptosis, we examined the effects of simvastatin (S) on inducible NO
synthase (iNOS) expression in cardiac myocytes, which may explain cardioprotection
observed in in vivo models. H9c2 cardiac myocytes were treated with S ± mevalonate (10
–
4
 mol/L), geranyl-geranyl-pyrophosphate or farnesyl-pyrophosphate (10 –4 mol/L) for 30
min, then stimulated for 0 - 48 h with interleukin (IL)-1α 20 ng/mL or tumor necrosis factor
(TNF)-α 20 ng/mL. Untreated H9c2 cells exhibited little iNOS which was markedly
increased by cytokines, as demonstrated by immunoblotting and nitrite assay. In the
absence of any cytotoxicity S concentration-dependently inhibited IL-1α/TNF-α-induced
expression of iNOS protein and mRNA (measured by reverse-transcrition polymerase
chain reaction), as well as nitrite production, an effect starting at 10-7 mol/L for IL-1α/
TNF-α stimulation of iNOS activity and protein expression, and at 10-8 mol/L for IL-1α/
TNF-α stimulation of iNOS mRNA expression, effects all reverted by mevalonate and ger-
anyl-geranyl pyrophosphate, but not by farnesyl-pyrophosphate. In the Table: *p<.05 vs
Multivariable Adjusted Mean Lumen Diameter Progression (um)
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P-trend
Total Chol 109 61 135 258 0.01
LDL 81 35 171 164 0.02
HDL 246 107 177 61 0.002
Triglycerides 80 126 135 237 0.005
ApoB 75 91 142 258 0.004
ApoA1 238 53 184 73 0.04
VLDL 60 103 154 223 0.002
Lp(a) 169 100 91 136 0.48
Chol:HDL 47 80 190 211 0.0002
ApoB:ApoA1 30 148 21 287 0.004
Non-HDL-C 20 140 133 287 <0.0001
End point Relative
Risk
95% CI P value 1st Q
(<111 µmol /L)
4th Q
( >167 µmol/L)
MACE 1.05 1.02-1.08 0.0007 11.5% 16.0%
Cardiac Death 1.03 1.05-1.13 <0.0001 4.2% 8.0%
Non fatal MI 1.01 0.96-1.06 0.6426 6.5 % 6.3 %
Stroke 1.03 0.97-1.08 0.3550 5.8% 5.5%
All Cause Mortality 1.01 1.01-1.01 <0.0001 11.2% 22.7%
Non-CV Mortality 1.01 1.00-1.01 0.0005 5.4% 10.1%
